Jame Abraham, MD, Co-Director of Cleveland Clinic’s Comprehensive Breast Cancer Program and Director of Breast Medical Oncology, discusses results of the 10-year follow-up of the BCIRG-006 clinical trial. These study results, presented at the 2015 San Antonio Breast Cancer Symposium, confirm the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer, including reduced risk of leukemia and cardiotoxicity.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Photo Credit: ©Russell Lee